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PURPOSE: It deserves investigation whether induction chemotherapy (IC) followed by intensity-modulated radiotherapy
(IMRT) is inferior to the current standard of IMRT plus concurrent chemotherapy (CC) in locoregionally advanced
nasopharyngeal carcinoma.METHODS:Patientswho received IC (94patients) orCC (302patients) plus IMRTat our center
betweenMarch2003 andNovember 2012were retrospectively analyzed. Propensity-scorematchingmethodwasused to
match patients in both arms at equal ratio. Failure-free survival (FFS), overall survival (OS), distant metastasis–free survival
(DMFS), and locoregional relapse–free survival (LRFS) were assessed with Kaplan-Meier method, log-rank test, and Cox
regression. RESULTS: In the original cohort of 396 patients, IC plus IMRT resulted in similar FFS (P= .565), OS (P= .334),
DMFS (P= .854), and LRFS (P= .999) to IMRT plus CC. In the propensity-matched cohort of 188 patients, no significant
survival differences were observed between the two treatment approaches (3-year FFS 80.3% vs 81.0%, P = .590; OS
93.4% vs 92.1%, P = .808; DMFS 85.9% vs 87.7%, P = .275; and LRFS 93.1% vs 92.0%, P = .763). Adjusting for the
knownprognostic factors inmultivariate analysis, IC plus IMRTdid not cause higher risk of treatment failure, death, distant
metastasis, or locoregional relapse. CONCLUSIONS: IC plus IMRT appeared to achieve comparable survival to IMRT plus
CC in locoregionally advanced nasopharyngeal carcinoma. Further investigations were warranted.
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Nasopharyngeal carcinoma (NPC) is a malignancy relatively rare in
Europe and the United States [1] but highly endemic in Southern
China [2] and Hong Kong [3]. Radiotherapy is the cornerstone of
initial treatment. Since the publication of INT-0099 trial [4], several
subsequent trials [5–9] have substantiated the survival benefits of
concurrent chemoradiotherapy, which was consequently recom-
mended as the standard of care in the subgroup of locoregionally
advanced disease.
330 IC plus IMRT versus IMRT plus CC in NPC OuYang et al. Translational Oncology Vol. 9, No. 4, 2016Interestingly, induction chemotherapy (IC) followed by
two-dimensional conventional radiotherapy (2DCRT) alone was
once reported to obtain encouraging response rates and improvement
in disease-free survival (DFS) [10–13]. It is expected to regress tumor
extension, avoid irradiation of organs at risk, prevent tumor
progression due to the long waiting time before radiotherapy, and
finally improve local and distant control. Actually, benefit has been
seen in reduction of both local and distant failures [14]. Even in the
era of concurrent chemotherapy (CC) plus intensity-modulated
radiotherapy (IMRT), IC appeared to achieve benefit in distant
metastasis–free survival (DMFS) [15] and even overall survival (OS)
[16]. Therefore, the combination of IC with concurrent chemora-
diotherapy is a popular option for cases of locoregionally advanced
disease with extensive involvement.
But unfortunately, a small number of patients fail to receive CC
after finishing IC in clinical reality. The main reasons include, but are
not restricted to, treatment costs, toxicities, and refusal for no reason.
Nothing is known about IC followed by IMRT, as it has barely been
compared head-to-head with the standard of care. Because more
recent randomized trials [17–19] comparing IMRT plus CC with or
without IC indicated no improvement of survival, IC followed by
IMRT might be a promising approach with inferior survival
outcomes but reduced toxicities. We thus retrospectively analyzed
data of 396 patients receiving IC or CC plus IMRT, especially using
propensity score matching method to mimic randomized trials [20].
This shall provide valuable effect assessment and pivotal reference for
the future randomized controlled trials.Materials and Methods
Patients
We enrolled 396 NPC patients who received treatment at our
center between March 2003 and November 2012. All patients were
diagnosed by history and physical examination, hematology and
biochemistry profiles, fiberoptic nasopharyngoscopy with biopsy,
magnetic resonance imaging (MRI) of nasopharynx and neck, chest
radiography or computed tomography (CT), abdominal sonography
or CT, and technetium-99m-methylene diphosphonate whole-body
bone scan or CT/MRI of bones, and/or [18F]fluorodeoxyglucose
positron emission tomography and CT. Patients were restaged based
on the 2010 International Union Against Cancer/American Joint
Committee on Cancer staging system for NPC.
Treatment
All patients were treated by IC or CC plus definitive IMRT. The
target volumes of IMRT were defined in accordance with the
International Commission on Radiation Units and Measurements
reports 50 and 62. The primary nasopharyngeal gross tumor volume
together with enlarged retropharyngeal nodes (GTVnx) and the
involved cervical lymph nodes (GTVnd) were determined from the
imaging, clinical, and endoscopic findings. Patients in the IC cohort
were examined by MRI 2 weeks after the final cycle of chemotherapy
to determine GTVnx and GTVnd. The first clinical tumor volume
(CTV1) was defined as the GTVnx plus a margin of 5 to 10 mm for
potential microscopic spread, including the entire nasopharynx
mucosa plus a 5-mm submucosal volume. The second CTV
(CTV2) was defined by adding a margin of 5 to 10 mm to CTV1
(when CTV2 was adjacent to critical organs such as brain stem and
spinal cord, the margin was reduced to 3 to 5 mm) and included theretropharyngeal lymphnodal regions, clivus, skull base, pterygoid
fossae, parapharyngeal space, inferior sphenoid sinus, posterior edge
of the nasal cavity and maxillary sinuses, and bilateral cervical
lymphatic area. Prescribed radiation doses were 68 Gy or greater to
the planning tumor volume (PTV) of GTVnx, 60 to 68 Gy to PTV of
GTVnd, 60 Gy or greater to PTV of CTV1, and 50 Gy or greater to
PTV of CTV2 in 30 to 33 fractions. Further details of IMRT have
been described previously [21]. IC regimen consisted of docetaxel/
paclitaxel plus cisplatin/nedaplatin, cisplatin/nedaplatin plus fluoro-
uracil, or docetaxel/paclitaxel plus cisplatin/nedaplatin plus fluoro-
uracil given every 3 weeks for 2 to 3 cycles before radiotherapy. CC
regimen consisted of 80 to 100 mg/m2 cisplatin given every 3 weeks
for 2 to 3 cycles, or 30 to 40 mg/m2 cisplatin given weekly for up to
7 cycles.
Follow-Up
Patients underwent conventional examination every 3 to 6 months
during the first 3 years and every 6 to 12 months thereafter until death
to detect possible locoregional relapse or distant metastasis. Actually,
the examination during this period was in line with that before
treatment. Confirmed locoregional relapse, distant metastasis, or
consistent disease received reirradiation, surgery, and/or chemother-
apy. Patients without recent examination tests in the medical records
were followed up by telephone.
Statistical Analysis
To reduce possible biases to a minimum in this retrospective
analysis, we used propensity score matching method [22] to match IC
plus IMRT cohort (case) with IMRT plus CC cohort (control).
Propensity scores were computed by logistic regression, taking into
account age, sex, histology (WHO II, differentiated nonkeratinizing
carcinoma; WHO III, undifferentiated nonkeratinizing carcinoma
[23]), T stage, N stage, and clinical stage. Propensity-matched cohorts
were thus established following matching without replacement at
equal ratio on those scores.
Characteristics of patients were compared using t test (continuous
variable), χ2 test (categorical variable), and standardized difference
[24]. Failure-free survival (FFS, time from treatment to evidence of
treatment failure), OS (time from treatment to death from any cause),
DMFS (time from treatment to the first distant metastasis), and
locoregional relapse–free survival (LRFS, time from treatment to the
first locoregional relapse) were estimated with Kaplan-Meier method
[25], log-rank test, and Cox proportional hazards model [26]. In the
propensity-matched cohort, survival outcomes were estimated using
stratified log-rank test by matched pairs and Cox proportional hazards
model with a robust variance estimator to account for the clustering
within matched pairs [27].
All statistical analyses were performed using IBM SPSS Statistics
version 23.0 and Stata version 12.0. Two-sided P values b .05 and
standardized difference N 0.10 [28] were considered to be significant.Results
Patients
Initially, 94 (23.7%) and 302 (76.3%) patients were treated with
IC plus IMRT and IMRT plus CC, respectively. Of note, patients
with advanced T stage, N stage, or overall clinical stage tended to
receive IC plus IMRT, whereas such characteristics as age and sex
scarcely affected treatment options. Following propensity score
Table 1. Baseline Characteristics of Patients Who Underwent Induction or CC Plus IMRT
The Original Unmatched Cohort The Propensity-Matched Cohort
IC + IMRT (n = 94) IMRT + CC (n = 302) P Standardized
Difference
IC + IMRT (n = 94) IMRT + CC (n = 94) P Standardized
Difference
No. (%) No. (%) No. (%) No. (%)
Age .872 0.018 .548 0.087
Mean 44.99 45.19 44.99 44.01
SD 11.59 10.34 11.59 10.69
Median 44.50 45.00 44.50 43.50
Sex .904 0.014 .866 0.025
Male 70 (74.5) 223 (73.8) 70 (74.5) 71 (75.5)
Female 24 (25.5) 79 (26.2) 24 (25.5) 23 (24.5)
Histology * .461 0.091 1.000 0.000
II 4 (4.3) 19 (6.3) 4 (4.3) 4 (4.3)
III 90 (95.7) 283 (93.7) 90 (95.7) 90 (95.7)
T stage .050 .978
T1 7 (7.4) 31 (10.3) 0.099 7 (7.4) 7 (7.4) 0.000
T2 15 (16.0) 59 (19.5) 0.094 15 (16.0) 13 (13.8) 0.060
T3 34 (36.2) 135 (44.7) 0.175 34 (36.2) 36 (38.3) 0.044
T4 38 (40.4) 77 (25.5) 0.322 38 (40.4) 38 (40.4) 0.000
N stage .124 .985
N0 14 (14.9) 43 (14.2) 0.019 14 (14.9) 13 (13.8) 0.030
N1 50 (53.2) 197 (65.2) 0.247 50 (53.2) 52 (55.3) 0.043
N2 23 (24.5) 46 (15.2) 0.233 23 (24.5) 23 (24.5) 0.000
N3 7 (7.4) 16 (5.3) 0.088 7 (7.4) 6 (6.4) 0.042
Clinical stage .004 1.000 0.000
II 10 (10.6) 69 (22.8) 0.331 10 (10.6) 10 (10.6)
III 40 (42.6) 140 (46.4) 0.077 40 (42.6) 40 (42.6)
IV 44 (46.8) 93 (30.8) 0.333 44 (46.8) 44 (46.8)
* Based on the criteria of WHO histological type (1991): II, differentiated nonkeratinizing carcinoma; III, undifferentiated nonkeratinizing carcinoma.
Figure 1. Kaplan-Meier survival curves for the IC arm and the CC arm in the original cohort of 396 patients. (A) FFS; (B) OS; (C) DMFS; (D) LRFS.
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with IMRT plus CC remained in the propensity-matched cohort. The
matched patients in both arms had balanced characteristics (Table 1).
Survival Outcomes
In the original unmatched cohort of 396 patients, median follow-up
time was 40.58 months (8.33-99.73 months) for the IC arm and 49.77
months (3.50-107.63 months) for the CC arm, respectively. Overall,
3-year FFS, OS, DMFS, and LRFS rates did not differ significantly
between the two arms (FFS 80.3% vs 82.0%, P = .565; OS 93.4% vs
93.8%,P = .334;DMFS 85.9% vs 87.7%,P = .854; and LRFS 93.1% vs
93.3%, P = .999; Figure 1, A–D). Accounting for age (continuous), sex,
T stage, and N stage in multivariate analysis, IC plus IMRT was not
associated with higher risk of death, locoregional relapse, or distant
metastasis than IMRT plus CC (Table 2).
In the propensity-matched cohort of 188 patients, median follow-up
time was 40.58 months (8.33-99.73 months) for the IC arm and 53.57
months (4.00-92.60 months) for the CC arm, respectively. In univariate
analysis, IC plus IMRT achieved similar survival to IMRT plus CC
(3-year FFS 80.3% vs 81.0%, P = .590; OS 93.4% vs 92.1%, P = .808;
DMFS 85.9% vs 87.7%,P = .275; and LRFS 93.1% vs 92.0%,P = .763;
Figure 2, A–D). In multivariate analysis, IC plus IMRT was also highly
comparable to IMRT plus CC in risk of treatment failure, death,
locoregional relapse, and distant metastasis (Table 2).
Grade 3 to 4 Hematological Toxicities
In the propensity-matched cohort, IC plus IMRT significantly
increased the incidence of grade 3 to 4 neutropenia, whereas IMRTTable 2. Summary of Important Prognostic Factors in Multivariate Analysis
The Original Unmatched Cohort
Hazard Ratio (95% CI)
FFS
IC + IMRT vs IMRT + CC 0.99 (0.61-1.61)
Age (continuous) 1.00 (0.98-1.02)
Sex 0.92 (0.56-1.49)
Histology 0.50 (0.23-1.11)
T stage 1.65 (1.27-2.14)
N stage 1.49 (1.12-1.98)
OS
IC + IMRT versus IMRT + CC 0.90 (0.46-1.75)
Age (continuous) 1.03 (1.00-1.05)
Sex 0.82 (0.42-1.62)
Histology 0.58 (0.21-1.64)
T stage 2.06 (1.40-3.03)
N stage 2.00 (1.37-2.90)
DMFS
IC + IMRT versus IMRT + CC 1.09 (0.60-2.00)
Age (continuous) 1.00 (0.97-1.02)
Sex 0.81 (0.43-1.50)
Histology 0.48 (0.19-1.24)
T stage 1.67 (1.21-2.31)
N stage 1.90 (1.36-2.64)
LRFS
IC + IMRT versus IMRT + CC 1.06 (0.45-2.47)
Age (continuous) 0.99 (0.96-1.02)
Sex 0.99 (0.44-2.22)
Histology 0.51 (0.15-1.71)
T stage 1.29 (0.86-1.93)
N stage 1.31 (0.80-2.12)
* Adjusted for age (continuous), sex, histology, T stage, and N stage.
† Adjusted for the same covariates with a robust variance estimator to account for the clustering within matplus CC tended to result in more leucopenia. The rates of grade 3 to 4
anemia and thrombocytopenia were similar in both cohorts (Table 3).
Discussion
Currently, no strong evidence from phase III randomized trials supports
the addition of IC to radiotherapy in locoregionally advanced NPC,
whereas CC plus radiotherapy is the standard recommended by National
Comprehensive Cancer Network because of the confirmed survival
benefits [29]. Thus, speculatively, IC followed by IMRT appears to be
inferior to IMRT plus CC. However, head-to-head comparison of these
two approaches in the present study showed no significant differences in
survival in both unmatched and matched cohorts. Actually, prior studies
had given some hints in favor of this insignificant difference.
A study from Japan [30] investigated IC regimen of cisplatin plus
5-fluorouracil plus methotrexate plus leucovorin (PFML) in 21 NPC
patients versus CC regimen of PFML or docetaxel plus cisplatin plus
5-fluorouracil in 25 patients, and observed no difference in survival.
Besides, a study from Taiwan [31] also found similar survival between 38
patients who underwent IC of MEPFL regimen (mitomycin, epirubicin,
cisplatin fluorouracil, and leucovorin) or PFL regimen (cisplatin,
fluorouracil, and leucovorin) and 90 patients receiving CC of cisplatin
or cisplatin and fluorouracil. Certainly, the small sample size in both
studies maybe had insufficient power to detect differences, if they existed.
More importantly, a large phase III randomized trial from Shanghai [32]
compared IC plus adjuvant chemotherapy (AC)withCCplus AC among
338 stage III to IVb (the 2002 International Union Against Cancer/
American Joint Committee on Cancer staging system) patients who
received 2 cycles of cisplatin and 5-fluorouracil before or during 2DCRTThe Propensity-Matched Cohort
P * Hazard Ratio (95% CI) P †
.963 0.82 (0.44-1.52) .522
.940 1.01 (0.98-1.04) .488
.730 1.04 (0.52-2.06) .911
.089 1.69 (0.20-14.09) .628
b .001 1.83 (1.24-2.69) .002
.006 1.62 (0.94-2.79) .081
.746 0.86 (0.39-1.89) .700
.064 1.03 (0.99-1.07) .113
.575 0.83 (0.34-1.99) .671
.306 – –
b .001 2.75 (1.59-4.76) b .001
b .001 2.25 (1.22-4.16) .009
.776 0.85 (0.40-1.82) .672
.690 0.99 (0.96-1.03) .741
.499 1.16 (0.52-2.60) .724
.129 – –
.002 2.22 (1.38-3.57) .001
b .001 2.28 (1.21-4.31) .011
.899 0.95 (0.30-3.00) .936
.457 0.99 (0.94-1.04) .684
.976 0.74 (0.19-2.96) .671
.276 0.49 (0.06-3.67) .486
.221 1.10 (0.64-1.89) .727
.282 1.01 (0.37-2.77) .981
ched pair.
Figure 2. Kaplan-Meier survival curves for the IC arm and the CC arm in the propensity-matched cohort of 188 patients. (A) FFS; (B) OS; (C)
DMFS; (D) LRFS.
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trial showed similar OS and DFS between IC and CC but more acute
toxicities from CC. As IMRT can achieve better LRFS and OS than
2DCRT [33], it is less likely to observe significant differences between IC
and CC in the IMRT era. This trial strongly supported the outcomes of
our present study despite the differences in chemotherapy regimens and
the addition of AC in both arms.
In addition, the outcomes of IMRT plus cisplatin-based CC in our
study were not inferior [17,34] but even superior [16,19] to those
from randomized trials, whereas the results of IC plus IMRT were
quite similar to those in randomized trials [16,17]. So it was not
unusual regarding the insignificant survival differences between IC
plus IMRT and IMRT plus CC in our study.
The major strength of this study was the head-to-head comparison
of IC with CC in NPC patients in the IMRT era using propensityTable 3. Grade 3 to 4 Hematological Toxicities in the Propensity-Matched Cohort
IC + IMRT
(n = 94)
IMRT + CC
(n = 94)
P Standardized
Difference
Leucopenia 14 (14.89%) 24 (25.53%) .069 0.267
Neutropenia 27 (40.91%) 10 (21.74%) .034 0.467
Anemia 5 (5.32%) 6 (6.38%) .756 0.045
Thrombocytopenia 6 (6.38%) 11 (11.70%) .204 0.186score matching and multivariate analysis. The presented data were
derived from a single institution in an endemic area with expertise in
diagnosing and treating this disease, which provided the utility in
treatment, especially the IMRT technique. The major limitation was
that the small number of patients in this study provided relative low
power to compare these two treatment approaches. Especially the
smaller sample size in the matched cohort may lead to skewed result.
But this report was currently the largest-scale head-to-head
comparison in contrast with prior publications such as the study by
Li et al. [35]. Further investigations with sufficient power are
definitely warranted. Data on DNA copy number of the Epstein-Barr
virus were missing in most of the cases, and acute nonhematological
and late toxicities were unavailable because of the retrospective design
and the long time span between the first and the last included case.
Owing to the low sensitivity rate of chest radiography compared with
chest CT, some patients might be delayed in detecting lung metastasis
and had falsely high DMFS rate as a consequence. But the intrinsic
differences in DMFS might scarcely change, as the chance of delay
was equal in patients in both arms. Another limitation caused by the
retrospective design was the heterogeneity of IC regimen and doses.
Besides, experienced locoregional relapse or distant metastasis was
updated from telephone call for some patients who completed the
examination tests out of our cancer center.
In conclusion, this study indicated no significant differences in
survival between IC and CC for NPC patients who received IMRT.
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